date,title,source
Oct-18-18,"Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018",PR Newswire
Oct-24-18,Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office,PR Newswire
Nov-01-18,Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting,PR Newswire
Nov-07-18,Trovagene Announces Third Quarter 2018 Highlights and Financial Results,PR Newswire
Nov-13-18,Trovagene Announces Launch of New Company Website,PR Newswire
Nov-15-18,"Trovagene, Inc. Receives Positive Nasdaq Listing Decision",PR Newswire
Nov-19-18,"Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Nov-21-18,What does TrovaGene Incs (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?,Simply Wall St.
Dec-03-18,New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML,PR Newswire
Dec-11-18,Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib,ACCESSWIRE
Jan-16-19,"The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen",Benzinga
Jan-23-19,Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer,PR Newswire
Jan-29-19,Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC),PR Newswire
Feb-14-19,Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference,PR Newswire
Feb-19-19,"Trovagene, Inc. Announces Reverse Stock Split",PR Newswire
Feb-28-19,Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting,PR Newswire
Mar-06-19,Trovagene Announces Fourth Quarter and Full-Year 2018 Results,PR Newswire
Mar-08-19,"What Should We Expect From TrovaGene, Inc.s (NASDAQ:TROV) Earnings Over The Next Few Years?",Simply Wall St.
Mar-08-19,TrovaGene News: Why TROV Stock Is Skyrocketing Today,InvestorPlace
Mar-12-19,Trovagene Regains Compliance with Nasdaq Listing Requirements,PR Newswire
Mar-13-19,Trovagene Receives Approximately $3.0 Million From Exercise of Warrants,PR Newswire
Mar-13-19,A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?,ACCESSWIRE
Apr-01-19,"Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels",PR Newswire
Apr-02-19,Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy,PR Newswire
